Trinity Biotech plc to Announce Third Quarter Fiscal Year 2016 Financial Results
October 12 2016 - 10:22AM
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, will report financial results for the
third quarter fiscal year 2016 on Tuesday, October 25, 2016. The
Company has scheduled a conference call for that same day, Tuesday,
October 25, 2016 at 11:00am ET (4:00pm BST) to discuss the results
of the quarter.
Interested parties can access the call by
dialing:
USA: |
|
1-844-861-5499 |
International: |
|
1-412-317-6581 |
Conference ID #: |
|
10094363 |
|
|
|
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/17674
A replay of the call can be accessed until November 1, 2016 by
dialing:
USA: |
|
1-877-344-7529 |
International: |
|
1-412-317-0088 |
Conference ID #: |
|
10094363 |
|
|
|
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/17674
About Trinity Biotech plcTrinity Biotech
develops, acquires, manufactures and markets diagnostic systems,
including both reagents and instrumentation, for the point-of-care
and clinical laboratory segments of the diagnostic market. The
products are used to detect infectious diseases and to quantify the
level of Haemoglobin A1c and other chemistry parameters in serum,
plasma and whole blood. Trinity Biotech sells direct in the United
States, Germany, France and the U.K. and through a network of
international distributors and strategic partners in over 75
countries worldwide. For further information please see the
Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States
Food and Drug Administration and other agencies, the impact of
competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission.
Contact:
Trinity Biotech plc
Kevin Tansley
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024